Knight Therapeutics | GUD - Interest Expense On Debt


Knight Therapeutics reported CAD3.92M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Akebia Therapeutics 349.66M 12.86M Jun/2026
Alaunos Therapeutics USD 1.07M 215K Jun/2023
Aurora Cannabis CAD 464K 234K Jun/2026
Avita Medical AUD 1.25M 100K Jun/2025
Canopy Growth CAD 12.68M 364K Jun/2026
Cronos Group USD 0 7K Sep/2024
Dianthus Therapeutics USD 4.44M 263K Sep/2024
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
IQVIA Holdings USD 203M 6M Sep/2026
Knight Therapeutics CAD 3.92M 1.56M Dec/2025
Moderna USD 10.96B 527M Jun/2026
Omeros USD 4.05M 5.16M Sep/2024
Organigram Holdings CAD 179K 127K Mar/2025
Organon & Co USD 106M 2M Sep/2026
Revvity USD 22.99M 1.73M Jun/2026
Tectonic Therapeutic USD 237.03M 9.54M Jun/2026
Tilray USD 6.7M 2.73M Jun/2025
Viatris USD 120.7M 600K Jun/2026
Xeris Pharmaceuticals USD 6.95M 63K Jun/2026